Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 May 21;15(5):e0233168.
doi: 10.1371/journal.pone.0233168. eCollection 2020.

Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot's acute neuroarthropathy

Dured Dardari  1   2   3 , Georges Ha Van  4 , Jocelyne M'Bemba  5 , Francois-Xavier Laborne  6 , Olivier Bourron  2   3   4 , Jean Michel Davaine  2   7 , Franck Phan  2   3   4 , Fabienne Foufelle  2 , Frédéric Jaisser  2 , Alfred Penfornis  1   8 , Agnes Hartemann  2   3   4
Affiliations
Clinical Trial

Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot's acute neuroarthropathy

Dured Dardari et al. PLoS One. .

Abstract

Objective: Aggressive antidiabetic therapy and rapid glycemic control are associated with diabetic neuropathy. Here we investigated if this is also the case for Charcot neuroarthropathy.

Research design and methods: HbA1c levels and other relevant data were extracted from medical databases of 44 cases of acute Charcot neuroarthropathy.

Results: HbA1c levels significantly declined from 8.25% (67mmol/mol) [7.1%-9.4%](54-79mmol/mol), at -6 months (M-6), to 7.40%(54mmol/mol) [6.70%-8.03%] (50-64 mmol/mol) during the six months preceding the diagnosis of Charcot neuroarthropathy (P <0.001).

Conclusions: HbA1c levels significantly declined during the six months preceding the onset of Charcot neuroarthropathy. This decline seems to be a associated factor with the appearance of an active phase of Charcot neuroarthropathy in poorly controlled patients with diabetic sensitive neuropathy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Gibbons CH, Treatment-induced neuropathy of diabetes. Curr Diab Rep 2017;17:127 10.1007/s11892-017-0960-6 - DOI - PubMed
    1. Gibbons CH, Freeman R, Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015;138:43–52. 10.1093/brain/awu307 - DOI - PMC - PubMed
    1. Trieb K, The Charcot foot: pathophysiology, diagnosis and classification. Bone Joint J 2016;98-B:1155–1159. 10.1302/0301-620X.98B9.37038 - DOI - PubMed
    1. Rajbhandari SM, Jenkins RC, Davies C, et al., Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002;45:1085–1096. 10.1007/s00125-002-0885-7 - DOI - PubMed
    1. Dardari D, Penfornis A, Amadou C, et al., Multifocal (tarsus and knee) activation ofneuroarthropathy following rapid glycaemic correction. J Diabetes Complications 2019; Dec;33(12) - PubMed

Substances